Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.51 |
| ▸ | ITGAV | P06756 | 16/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.43 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7401929 | 0.85 | ITGB3 (0.47) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL5022907 | 0.85 | ITGB3 (0.61) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL7346806 | 0.85 | ITGB3 (0.61) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL7980585 | 0.84 | ITGB3 (0.45) | ITGB3ITGAVITGA2B | |
| SCHEMBL7399995 | 0.83 | ITGB3 (0.43) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL13059981 | 0.81 | ITGB3 (0.54) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL7403041 | 0.80 | ITGB3 (0.42) | ITGB3ITGAVITGA2B | |
| SCHEMBL6111422 | 0.79 | ITGB3 (0.60) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| Iodide SCHEMBL7403601 | 0.79 | ITGB3 (0.60) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL5027067 | 0.79 | ITGB3 (0.60) | ITGB3ITGAVITGA2BITGB5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | claimed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | claimed |
| US-6214834-B1 | ANGIOGENESIS INHIBITORS; ANTIINFLAMMATORY AGENTS; ANTICANCER AGENTS | DUPONT PHARMACEUTICALS COMPANY | 2001-04-10 | — | — | US | disclosed |
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |